PMID- 32792883
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 1642-395X (Print)
IS  - 2299-0046 (Electronic)
IS  - 1642-395X (Linking)
VI  - 37
IP  - 3
DP  - 2020 Jun
TI  - Effect of methotrexate treatment on the expression of epidermal-fatty 
      acid-binding protein (E-FABP) and apolipoproteins in patients with psoriasis.
PG  - 401-406
LID - 10.5114/ada.2020.96109 [doi]
AB  - INTRODUCTION: Epidermal-fatty acid-binding protein (E-FABP) is a marker of 
      transiently amplifying cells which are formed from stem cells in epidermis. Their 
      role is an uptake of fatty acids and metabolism. Psoriatic keratinocytes 
      overexpress E-FABPs, which leads to acanthosis and may explain the lipid's 
      disturbances in psoriasis. AIM: Assessment of FABP and apolipoprotein expression 
      in patients treated with methotrexate (MTX). MATERIAL AND METHODS: FABP 
      expression in the lesional and perilesional psoriatic skin from 11 male patients 
      compared to 5 healthy skin samples were evaluated by immunohistochemistry. FABP, 
      apolipoprotein A1 (ApoA1) and B (ApoB) serum levels were assessed by ELISA. These 
      parameters were evaluated before and after treatment with subcutaneous MTX (15 
      mg/wk for 12 weeks). RESULTS: Expression of E-FABP was lower in the control group 
      than in the lesional and perilesional psoriatic skin, before and after treatment. 
      After treatment the expression decreased in the lesional and perilesional skin. 
      Serum E-FABP was higher in the control group (482.855 +/-240.550 pg/ml) compared to 
      patients, but not statistically significantly. After MTX treatment, a 
      statistically significant reduction was observed in psoriatic patients. ApoA1 
      levels did not differ in the control and patients groups, both before and after 
      treatment. In contrast, ApoB levels did not differ statistically between the 
      control group (1447.126 +/-311.11 ng/ml) and patients before treatment, while they 
      were the lowest after treatment (1081.67 +/-117.83 ng/ml vs. 808.306 +/-103.72 ng/ml; 
      p < 0.01). CONCLUSIONS: Our study confirms the beneficial effect of MTX, not only 
      as an anti-proliferative effect, but also reducing the cardiovascular risk by 
      decreasing atherogenic ApoB.
CI  - Copyright: (c) 2020 Termedia Sp. z o. o.
FAU - Owczarczyk-Saczonek, Agnieszka
AU  - Owczarczyk-Saczonek A
AD  - Department of Dermatology, Sexually Transmitted Diseases and Clinical Immunology, 
      Warmia and Mazury University, Olsztyn, Poland.
FAU - Czerwinska, Joanna
AU  - Czerwinska J
AD  - Department of Dermatology, Sexually Transmitted Diseases and Clinical Immunology, 
      Warmia and Mazury University, Olsztyn, Poland.
FAU - Orylska, Malgorzata
AU  - Orylska M
AD  - Department of Dermatology, Sexually Transmitted Diseases and Clinical Immunology, 
      Warmia and Mazury University, Olsztyn, Poland.
FAU - Placek, Waldemar
AU  - Placek W
AD  - Department of Dermatology, Sexually Transmitted Diseases and Clinical Immunology, 
      Warmia and Mazury University, Olsztyn, Poland.
LA  - eng
PT  - Journal Article
DEP - 20200716
PL  - Poland
TA  - Postepy Dermatol Alergol
JT  - Postepy dermatologii i alergologii
JID - 101168357
PMC - PMC7394159
OTO - NOTNLM
OT  - apolipoprotein
OT  - fatty acid-binding protein
OT  - methotrexate
OT  - psoriasis
COIS- The authors declare no conflict of interest.
EDAT- 2020/08/15 06:00
MHDA- 2020/08/15 06:01
PMCR- 2020/06/01
CRDT- 2020/08/15 06:00
PHST- 2018/10/14 00:00 [received]
PHST- 2018/11/05 00:00 [accepted]
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2020/08/15 06:01 [medline]
PHST- 2020/06/01 00:00 [pmc-release]
AID - 96109 [pii]
AID - 10.5114/ada.2020.96109 [doi]
PST - ppublish
SO  - Postepy Dermatol Alergol. 2020 Jun;37(3):401-406. doi: 10.5114/ada.2020.96109. 
      Epub 2020 Jul 16.